Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico. LP-284 has the potential to address B-cell lymphomas and other B-cell driven malignancies addressing a $4+ billion annual market need LP-28... L'articolo Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy è un contenuto originale di 01net.

Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, marking a pivotal step in the …